» Articles » PMID: 21900282

Human Leucocyte Antigen Risk Alleles for Psoriatic Arthritis Among Patients with Psoriasis

Overview
Journal Ann Rheum Dis
Specialty Rheumatology
Date 2011 Sep 9
PMID 21900282
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Aim Genes that differentiate patients with psoriatic arthritis (PsA) from those with cutaneous psoriasis (PsC) may serve as markers for the development of PsA in patients with psoriasis. The authors aimed to identify human leucocyte antigen (HLA) alleles that are associated with the development of PsA in patients with psoriasis.

Methods: 712 adult patients with PsA, 335 adult patients with PsC and 713 healthy controls were genotyped for HLA-A, HLA-B, HLA-C, HLA-DR and HLA-DQ alleles. Differences in allelic distributions for each of the HLA loci were compared using a likelihood ratio test. Logistic regression analysis of multiple loci was performed to account for linkage disequilibrium. Haplotype information was inferred using the expectation-maximisation algorithm (given HLA-C and HLA-B genotypes) and analysed similarly.

Results: The following HLA alleles were found to be significantly associated with patients with PsA compared to patients with PsC in multivariate regression analysis: B*08 (OR 1.61, p=0.009), B*27 (OR 5.17, p<0.0001), B*38 (OR 1.65, p=0.026) and C*06 (OR 0.58, p=0.0002). HLA-B*27, HLA-B*38 and HLA-C*06 frequencies were also significantly higher in patients with PsA than in healthy controls (B*27: OR 3.05, p<0.0001; B*38: OR 5.9, p<0.0001; HLA-C*06: OR 1.71, p<0.0001). The following haplotypes were independently associated with PsA compared to PsC: HLA-B*18-C*07 (OR 10.1, p=0.004), HLA-B*27-C*01 (OR 41.1, p<0.0001), HLA-B*27-C*02 (OR 19.9, p<0.0001), HLA-B*38-C*12 (OR 2.9, p=0.01), HLA-B*08-C*07 (OR 2.6, p=0.004) and HLA-B*57-C*06 (OR 0.5, p=0.03).

Conclusions: Certain HLA-B and HLA-C alleles confer susceptibility to PsA among patients with psoriasis and may be used to identify patients with PsC who may develop PsA.

Citing Articles

Looking back on 51 years of the Carol Nachman Prize in Rheumatology-significance for the field of spondyloarthritis research.

Braun J, Sieper J, Marker-Hermann E Z Rheumatol. 2024; 83(7):563-574.

PMID: 38864856 PMC: 11442482. DOI: 10.1007/s00393-024-01496-w.


From Psoriasis to Psoriatic Arthritis: Decoding the Impact of Treatment Modalities on the Prevention of Psoriatic Arthritis.

Watad A, Zabotti A, Patt Y, Gendelman O, Dotan A, Ben-Shabat N Rheumatol Ther. 2024; 11(4):963-976.

PMID: 38847993 PMC: 11264659. DOI: 10.1007/s40744-024-00680-3.


Psoriasis and Psoriatic Arthritis-Associated Genes, Cytokines, and Human Leukocyte Antigens.

Zalesak M, Danisovic L, Harsanyi S Medicina (Kaunas). 2024; 60(5).

PMID: 38792999 PMC: 11123327. DOI: 10.3390/medicina60050815.


Differences between psoriatic arthritis and psoriasis in multi-omics.

Gao S, Song H Arch Dermatol Res. 2024; 316(6):217.

PMID: 38787526 DOI: 10.1007/s00403-024-03018-9.


JAKinhibs in Psoriatic Disease: Analysis of the Efficacy/Safety Profile in Daily Clinical Practice.

Bizzarri F, Ruiz-Villaverde R, Morales-Garrido P, Ruiz-Carrascosa J, Cebolla-Verdugo M, Prados-Carmona A Diagnostics (Basel). 2024; 14(10).

PMID: 38786286 PMC: 11119658. DOI: 10.3390/diagnostics14100988.